LIXIANA® is a once-daily, oral, direct factor Xa inhibitor that combines:

Effective prevention of VTE in Hokusai-VTE
Comparable to wafarin in reduction of symptomatic recurrent VTE across a broad range of eligible patients1
Superior reduction in clinically relevant bleeding in Hokusai-VTE
Superior to warfarin in reducing clinically relevant bleeding (composite of major* and clinically relevant nonmajor [CRNM] bleeding).§
  • *

    Major bleeding in nonsurgical patients was defined as2

    1. Fatal bleeding, and/or
    2. Symptomatic bleeding in critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome, and/or
    3. Bleeding causing a fall in haemoglobin level of 20 g/L-1 (1.24 mml/L-1) or more, or leading to transfusing of 2 or more units of whole blood or red cells.
  • §

    Clinically relevant nonmajor bleeding was defined as overt bleeding not meeting the criteria for major bleeding* but associated with medical intervention, unscheduled contact (visit or telephone call) with a physician, (temporary) cessation of study treatment, or associated with any other discomfort such as pain, or impairment of activities of daily life.1

  • One or more of the following factors: moderate renal impairment (creatinine clearance of 30-50 mL/min), low body weight (≤60 kg/132 lbs), concomitant use of P-glycoprotein inhibitors (eg, cyclosporine, dronedarone, ketoconazole, erythromycin).3